$1.34 Billion is the total value of Consonance Capital Management LP's 31 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 66.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $137,941,000 | +17.4% | 7,180,700 | +17.2% | 10.27% | +43.3% |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $128,048,000 | +58.1% | 1,350,360 | +46.9% | 9.54% | +92.9% |
| AUPH | Buy | AURINIA PHARMACEUTICALS INC | $100,255,000 | -25.3% | 6,909,374 | +4.3% | 7.46% | -8.9% |
| CCXI | Buy | CHEMOCENTRYX INC | $92,325,000 | +22.8% | 2,297,779 | +20.8% | 6.88% | +49.8% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $80,522,000 | +75.2% | 823,165 | +131.1% | 6.00% | +113.8% |
| OMER | Buy | OMEROS CORP | $59,896,000 | +33.0% | 4,479,872 | +40.2% | 4.46% | +62.3% |
| CDNA | Buy | CAREDX INC | $58,083,000 | +26.9% | 2,660,716 | +25.4% | 4.32% | +54.8% |
| AKBA | New | AKEBIA THERAPEUTICS INC | $53,979,000 | – | 7,121,283 | +100.0% | 4.02% | – |
| QURE | Buy | UNIQURE NV | $48,999,000 | -26.4% | 1,032,636 | +11.2% | 3.65% | -10.2% |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $47,093,000 | +22.5% | 3,175,535 | +69.1% | 3.51% | +49.5% |
| PRNB | New | PRINCIPIA BIOPHARMA INC | $40,955,000 | – | 689,718 | +100.0% | 3.05% | – |
| CYTK | New | CYTOKINETICS INC | $40,466,000 | – | 3,432,232 | +100.0% | 3.01% | – |
| AXGN | Buy | AXOGEN INC | $37,087,000 | -30.6% | 3,566,054 | +19.4% | 2.76% | -15.3% |
| KNSA | New | KINIKSA PHARMACEUTICALS LTD | $34,687,000 | – | 2,240,779 | +100.0% | 2.58% | – |
| Buy | APTOSE BIOSCIENCES INC | $34,431,000 | +27.2% | 5,796,482 | +21.5% | 2.56% | +55.3% | |
| CHRS | New | COHERUS BIOSCIENCES INC | $32,764,000 | – | 2,020,002 | +100.0% | 2.44% | – |
| KRYS | Buy | KRYSTAL BIOTECH INC | $28,304,000 | +150.8% | 654,586 | +221.2% | 2.11% | +206.0% |
| XENE | New | XENON PHARMACEUTICALS INC | $22,449,000 | – | 1,979,669 | +100.0% | 1.67% | – |
| BLU | New | BELLUS HEALTH INC NEW | $15,943,000 | – | 1,597,503 | +100.0% | 1.19% | – |
| AXGT | New | AXOVANT GENE THERAPIES LTD | $8,914,000 | – | 3,653,303 | +100.0% | 0.66% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.